Combining Antigen-Specific Vaccination And Targeted Radionuclide Therapy In A Murine Prostate Model

Combining antigen-specific vaccination and targeted radionuclide therapy in a murine prostate model

Dr. Tagawa on BRCA2 in Patients with Prostate Cancer Receiving PSMA-Targeted Radionuclide Therapy

Combining a DNA vaccine with pembrolizumab for mCRPC

Developing Vaccines as a Treatment for Prostate Cancer

Combining PRRT with Targeted Therapy

Unanswered questions in PSMA-targeted radionuclide therapy

Prostate Cancer Immunotherapy Trials

Grand Rounds in Urology

Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC

177Lu-PSMA-617 radionuclide therapy in mCRPC

Vaccines are a promising direction for prostate cancer immunotherapy

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer

Synthetic DNA Vaccines Against Prostate Cancer

Genes and Cancer

Immune, Hormone, & Radiation Combined for Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

Prostate Cancer Research Institute

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC

Asessing the pTVG-HP Plasmid DNA vaccine in patients with mCRPC

New Views of Cancer Vaccine Development - Research on Aging

University of California Television (UCTV)

VBIR vaccine shows promise in prostate cancer: Phase I trial results and immunotherapy potential

Prostate-Specific Membrane Antigen Activated Prodrug and Imaging Agents

Cancer and Vaccination - Dr. Claudia Gravekamp

SENS Research Foundation

5:00 PM Therapeutic vaccines: The right targets at the right times - Douglas G. McNeel

Genitourinary Cancers